Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the potential of having “off-the-shelf” chimeric antigen receptor T-cell (CAR-T) therapies, outlining existing studies and results so far, and highlighting the need for increased lymphodepletion when using allogeneic CAR T-cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.